Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia (Post-authorization safety study in type 2 diabetic)

25/07/2017
14/03/2024
EU PAS number:
EUPAS20025
Study
Ongoing
Documents
Study protocol
Initial protocol
English (722.02 KB - PDF) View document
Updated protocol
English (474.85 KB - PDF) View document
Study results
Study report
Other information